Sai Life Sciences Limited IPO (Sai Life Sciences Limited IPO) Details

Incorporation Year: January 1999
Industry: Pharmaceutical Contract Research, Development, and Manufacturing (CRDMO)

---

Business Profile

Sai Life Sciences Limited specializes in the research, development, and manufacturing of small-molecule new chemical entities (NCEs), catering to biotech firms and global pharmaceutical companies. The company offers customized, high-quality, and responsive services, providing critical support across the drug discovery, development, and manufacturing lifecycle.

Key Service Offerings:

1. CRDMO Capabilities:
   • Integrated services for discovery, development, and manufacturing of molecules.
2. CRO Services:
   • Integrated discovery capabilities across biology, chemistry, and drug metabolism and pharmacokinetics (DMPK).
3. CDMO Services:
   • Chemistry, manufacturing, and control (CMC) for both commercial and under-development molecules.

---

Key Metrics and Operations

• Client Base:

  • Provided services to over 280 innovator pharmaceutical companies in FY2024, including 230 clients in September 2024 alone.
  • Collaborated with 18 of the top 25 global pharmaceutical companies by revenue in 2023.

• Geographical Reach:

  • Operations span the US, the UK, Europe, and Japan, supported by a global business development team of 16 professionals.

• Scientific Expertise:

  • As of September 30, 2024:
    • 2,353 scientific staff, including:
      • 302 Ph.D.s.
      • 1,475 master’s degree holders.
    • Total employee count: 3,135.

---

Competitive Strengths

1. Integrated CRDMO Model:
   • Comprehensive platform for drug discovery, development, and manufacturing.
2. Expertise Across Disciplines:
   • Strong capabilities in biology, chemistry, DMPK, and CMC processes.
3. Diverse Molecule Portfolio:
   • Experience with both commercial and under-development molecules.
4. Customization and Responsiveness:
   • Tailored services for both small and large clients, ensuring adaptability.
5. Strong Growth Metrics:
   • Revenue CAGR and EBITDA CAGR growth from FY2022 to FY2024.

---

Vision and Strategic Mission

Sai Life Sciences is committed to addressing critical healthcare challenges and aims to develop innovative medicines that tackle currently incurable conditions. By leveraging its scientific expertise and CRDMO capabilities, the company aspires to make a transformative impact on the future of healthcare.

---

Key Differentiators

• Proven Track Record: Delivered a wide range of NCE development programs for over 24 years.
• Global Presence: Strong foothold in key pharmaceutical markets, including the US, UK, Europe, and Japan.
• Client-Centric Approach: Focus on quality, price, and responsiveness as core value propositions.
• Scientific Excellence: Advanced team of professionals with specialized degrees driving innovation and efficiency.

Sai Life Sciences Limited continues to stand out as a trusted partner for global biotech and pharmaceutical innovators, blending expertise, adaptability, and reliability to meet the dynamic needs of the healthcare sector.